Caecilie Skejoe1, Aida S Hansen1, Kristian Stengaard-Pedersen2, Peter Junker3, Kim Hoerslev-Pedersen4, Merete L Hetland5, Mikkel Oestergaard5, Stinne Greisen1, Malene Hvid1,6, Mette Deleuran7,8, Bent Deleuran1,2. 1. Department of Biomedicine, Aarhus University Denmark. 2. Department of Rheumatology, Aarhus University Hospital Denmark. 3. Department of Rheumatology, Odense University Hospital Denmark. 4. King Christian 10th Hospital for The Rheumatic Diseases, and University of Southern Denmark Denmark. 5. Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital Denmark. 6. Department of Clinical Medicine, Aarhus University Denmark. 7. Department of Dermato-Venerology, Aarhus University Hospital Denmark. 8. Department of Clinical Immunology, Aarhus University Hospital Denmark.
Abstract
OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoimmune disease, that involves both pro- and anti-inflammatory mechanisms. The purpose of the present study is to investigate T-cell immunoglobulin and mucin domain 3 (Tim-3) in RA. METHODS: Plasma levels of soluble (s) Tim-3 in early RA (n=98), were followed, to evaluate association with treatment and disease activity, acquired from a prospective collected biobank (clinicaltrials.gov (NCT00660647)). We also investigate the influence of Tim-3 on spontaneous cytokine production in synovial fluid mononuclear cells (SFMC) from RA patients after addition of neutralizing anti-Tim-3's antibodies, either alone or in combination with neutralizing anti-Programmed Cell death protein 1 (PD-1) antibodies. RESULTS: Long-time stimulated CD4 T-cells expressed high levels of Tim-3, but tended to decrease their PD-1 expression. Tim-3 expression was exclusively seen co-expressed with PD-1 by CD3, CD4, CD45RO positive cells in the inflamed RA joint. Addition of neutralizing Tim-3 antibodies increased the secretion of IFNγ and MCP-1, in SFMC cultures from RA. Whereas neutralizing anti-PD-1 antibodies showed a broader impact on cytokine production. Finally, we observed that soluble Tim-3 is increased in plasma and is associated with disease activity in early RA. CONCLUSION: Taken together, our findings indicate disease-suppressive functions of Tim-3 in RA. AJCEI
OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoimmune disease, that involves both pro- and anti-inflammatory mechanisms. The purpose of the present study is to investigate T-cell immunoglobulin and mucin domain 3 (Tim-3) in RA. METHODS: Plasma levels of soluble (s) Tim-3 in early RA (n=98), were followed, to evaluate association with treatment and disease activity, acquired from a prospective collected biobank (clinicaltrials.gov (NCT00660647)). We also investigate the influence of Tim-3 on spontaneous cytokine production in synovial fluid mononuclear cells (SFMC) from RA patients after addition of neutralizing anti-Tim-3's antibodies, either alone or in combination with neutralizing anti-Programmed Cell death protein 1 (PD-1) antibodies. RESULTS: Long-time stimulated CD4 T-cells expressed high levels of Tim-3, but tended to decrease their PD-1 expression. Tim-3 expression was exclusively seen co-expressed with PD-1 by CD3, CD4, CD45RO positive cells in the inflamed RA joint. Addition of neutralizing Tim-3 antibodies increased the secretion of IFNγ and MCP-1, in SFMC cultures from RA. Whereas neutralizing anti-PD-1 antibodies showed a broader impact on cytokine production. Finally, we observed that soluble Tim-3 is increased in plasma and is associated with disease activity in early RA. CONCLUSION: Taken together, our findings indicate disease-suppressive functions of Tim-3 in RA. AJCEI
Authors: K Hørslev-Petersen; M L Hetland; L M Ørnbjerg; P Junker; J Pødenphant; T Ellingsen; P Ahlquist; H Lindegaard; A Linauskas; A Schlemmer; M Y Dam; I Hansen; T Lottenburger; C G Ammitzbøll; A Jørgensen; S B Krintel; J Raun; J S Johansen; M Østergaard; K Stengaard-Pedersen Journal: Ann Rheum Dis Date: 2015-10-21 Impact factor: 19.103
Authors: Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour Journal: J Exp Med Date: 2010-09-06 Impact factor: 14.307
Authors: William D Hastings; David E Anderson; Nasim Kassam; Ken Koguchi; Edward A Greenfield; Sally C Kent; Xin Xiao Zheng; Terry B Strom; David A Hafler; Vijay K Kuchroo Journal: Eur J Immunol Date: 2009-09 Impact factor: 5.532
Authors: Douglas B Johnson; Ryan J Sullivan; Patrick A Ott; Matteo S Carlino; Nikhil I Khushalani; Fei Ye; Alexander Guminski; Igor Puzanov; Donald P Lawrence; Elizabeth I Buchbinder; Tejaswi Mudigonda; Kristen Spencer; Carolin Bender; Jenny Lee; Howard L Kaufman; Alexander M Menzies; Jessica C Hassel; Janice M Mehnert; Jeffrey A Sosman; Georgina V Long; Joseph I Clark Journal: JAMA Oncol Date: 2016-02 Impact factor: 31.777